Background: Postpartum depression is seen in approximately 13% of women who have recently given birth; unfortunately, it often remains untreated. Important causes for undertreatment of this disorder are providers' and patients' lack of information about the effectiveness of various treatments, and their concerns about the impact of treatment on nursing infants. This article presents research-based evidence on the benefits of various treatments for postpartum depression and their potential risks to nursing infants.
Postpartum depression, observed in approximately 13% of women who have recently given birth, 1 is the most prevalent serious complication of pregnancy. It is classified as a major depressive disorder and as such is characterized by a variety of mental and physical symptoms that produce significant distress and detrimental changes in life functions (Table 1). According to the postpartum onset modifier of major depressive disorder, depressive symptoms begin within the first 4 weeks after delivery; however, it has been shown that women continue to remain at risk for mental disorders even several months after delivery. 2 Postpartum depression is distinguishable from other postpartum mental disorders. The transient "postpartum blues" occur in a majority of mothers at some time within the first 2 weeks after delivery and are characterized by dysphoria, mood lability, crying, anxiety, insomnia, poor appetite, and irritability. 3 The more serious but relatively rare postpartum psychosis (prevalence of 0.1%-0.2%), 3 is associated with such symptoms as loose thought associations, hallucinations, delusions, and disorganized or catatonic behavior. Although the consequences of postpartum depression are usually not as severe as those of postpartum psychosis, they can have a significant, negative impact on the lives of not only mothers but also other family members. Mothers themselves might experience physical, marital, parental, social, and vocational difficulties. 4 Their depression can, in some cases, also adversely affect their infants; studies have noted associations between maternal depression and impaired maternal-infant interactions, 5 cognitive and emotional development, 6 and anxiety and lower self-esteem. 7 Given the potential serious consequences of postpartum depression, it is imperative that health professionals caring for mothers of infants appropriately manage this disorder. A common barrier to providing adequate care is failure to recognize the problem in the first place. Therefore, the US Preventive Services Task Force has recently recommended that adults be screened for depression in clinical practices that have systems in place to as-sure accurate diagnosis, effective treatment, and follow-up. 8 In a study of 342 women, use of the Edinburgh Postnatal Depression Scale (EPDS) to screen for depression at approximately 6 weeks postpartum improved the rate of depression diagnosis from 3.7% to 10.7%. 9 Although the EPDS is the most commonly used screening tool for postpartum depression in research studies, 3 the Task Force suggests that screening with a simple 2-question tool, developed by Whooley et al (1997), 10 may be as effective as longer instruments. The tool includes these questions: (1) "Over the past 2 weeks, have you felt down, depressed, or hopeless?" and (2) "Over the past 2 weeks, have you felt little interest or pleasure in doing things?" 10 A positive response to either question indicates a positive screen and should be followed by an expanded history to confirm the diagnosis of depression.
Once the diagnosis of postpartum depression has been established, it should be treated using methods similar to those used for non-postpartum major depressive disorder. These consist of (1) patient education regarding depression, including the biologic basis of depression, treatment options, therapeutic and adverse effects of antidepressant drugs, desired duration of treatment (usually several months or longer), and the need for a healthy lifestyle and social support and (2) the selection of an active treatment modality (usually antidepressant medication and/or psychotherapy) through shared decision making between the patient and provider. 11 Notably, the treatment of depression in the postpartum period may be more challenging than in other stages of life. Patients and physicians often have concerns about the use of psychotropic medications in breastfeeding women and, related to this, questions about other viable treatment options for breastfeeding women. Therefore, the purpose of this article is to review empirically based information about the effectiveness of various pharmacologic and nonpharmacological treatment modalities for postpartum depression and antidepressant drug effects on nursing infants.
Methods
A literature search on treatments for postpartum depression (ie, drug therapy, individual and group therapy, and other support therapy) was performed by searching MEDLINE, 1966 to August 2002. The key search terms used were "postpartum depression," "postnatal depression," "puerperal depression," "treatment," "therapy," "drug therapy," "psychotherapy," and "breastfeeding." Current Contents was also searched from 1994 to August 2002 using the key terms "postpartum depression," "puerperal depression," "postnatal depression," "therapy," "psychotherapy," and "group therapy." Searches were mostly limited to randomized controlled trials. Secondary searches were performed using the bibliographies of review articles [12] [13] [14] and other articles obtained through these search meth- 
Results

Antidepressant Treatment
Numerous studies have found antidepressant drugs to be effective in treating general depression. 15 Although newer antidepressants [eg, selective serotonin reuptake inhibitors (SSRIs)] are as efficacious as the older tricyclic antidepressants (TCAs), the SSRIs are the drugs of choice for treating depressive disorders because of their greater tolerability and their relative safety if taken in overdose. 15, 16 Common side effects for TCAs include anticholinergic effects, weight gain, sedation, and orthostatic hypotension, whereas adverse effects for SSRIs include nausea, anorexia, diarrhea, headache, anxiety, nervousness, insomnia, drowsiness, sexual dysfunction, and increased sweating. 17 Less attention has been given to the efficacy of antidepressant medications for postpartum depression. Uncontrolled studies have typically shown improvement in postpartum depressive symptoms after treatment with antidepressants such as sertraline, 18 fluvoxamine, 19 and venlafaxine. 20 However, because depression normally improves over time even without treatment, it is difficult to know whether the improvement in depressive symptoms seen in these studies can be attributed to antidepressant drugs or other factors. A fourth study controlled for such factors by randomizing 87 subjects to 4 groups: fluoxetine or placebo plus 1 or 6 sessions of counseling. Results showed that fluoxetine was better than placebo, and 6 sessions of counseling were better than 1, but there was no added benefit to combining fluoxetine and multiple counseling sessions. 21 This trial provides experimental evidence that antidepressant drug therapy is effective in treating postpartum depression.
Antidepressant Treatment in Breastfeeding Mothers
A deterrent to mothers' use of antidepressant medications in the postpartum period is concern about potential adverse effects on the nursing infant. 22 Several studies have been conducted to inform these concerns. Table 2 reports infant serum levels of antidepressants and behavioral outcomes for breastfeeding newborns whose mothers were treated with a variety of antidepressants, including several SSRIs and TCAs. Infant serum levels of antidepressants, rather than breast milk concentrations, are reported, because serum levels are considered to be more direct determinants of drug exposure. 13 For most of the infants in these studies, serum levels of antidepressant drugs were either not detectable or very low. Exceptions to this were relatively high infant levels of nefazodone in 1 infant 68 and fluoxetine in 3 other infants. 32, 33 In each of these cases, disconcerting symptoms were seeneg, increased crying, vomiting, diarrhea, colic, and decreased sleep with fluoxetine, 32, 33 and drowsiness, lethargy, hypothermia, and poor feeding with nefazodone. 68 The infant whose mother had taken nefazodone was preterm, which may have contributed to the problem. Adverse clinical outcomes were also seen in 1 infant exposed to citalopram, 24 2 infants exposed to doxepin, 58,60 1 infant exposed to nefazodone, 68 and infants from 3 additional studies with fluoxetine. 27, 29, 31 The largest fluoxetine study compared 64 fluoxetine-treated mother-infant pairs with 38 non-treated motherinfant pairs. Statistically significant reductions in infant weight were seen in the fluoxetine group (average deficit, 392 g between 2 weeks and 6 months of age). 29 Given the various concerns regarding antidepressant treatment for breastfeeding women, the US Food and Drug Administration has not approved any antidepressant for use during lactation. 47 These studies provide helpful clinical information about antidepressant transmission to nursing infants, but their methodological weaknesses must also be considered. First, many of the studies listed in Table 2 used a very low sample size; in the majority of reports, only 1 or 2 infants are represented. Second, sampling and measurement methods vary between studies; older studies tend to use less sensitive methods. Third, nursing infants generally ingest relatively small amounts of these drugs-less than 1% of the maternal dose; 71 con- None *Lower limits of detection are shown in parentheses (in nanograms per milliliter) when the specified drug was not detected in the infant's serum. Lower limits vary with the precision of the laboratory method. ЈSafeЈ infant serum levels of antidepressants have not been established, in that safety profiles depend on the age of the infant (healthy term infants more than 10 weeks old have a lower risk of negative effects), the characteristics of the drug, and concentrations of its metabolites. 13 sequently, their serum levels of antidepressants tend to be very low. However, infants' serum levels of antidepressants might not be representative of their brain levels, because brain tissue is very lipophilic. Fourth, most of the studies had relatively short-term follow-up, lasting weeks to months over the course of antidepressant treatment but not beyond the treatment period. An exception to this is the study by Piontek et al 37 of fluvoxamine-exposed infants, where no ill effects were seen after 2 to 3 years of follow-up.
Maternal antidepressant therapy carries risks for nursing infants, but untreated depression is also risky-for mothers and infants. Thus, for each patient, the risks and benefits of treatment must be carefully weighed. If the potential benefits are thought to be greater, paroxetine, sertraline, and nortriptyline could be considered as initial drug therapy options. Each of these medications has been studied in more than 20 mother-infant pairs, with no adverse infant-related events observed. Fluoxetine should be avoided, and citalopram, doxepin, and nefazodone used only cautiously, because adverse effects have been associated with their use. It is generally recommended that treatment be initiated with an SSRI because of ease of administration and low toxicity.
14 If the patient responds to an initial trial of medication lasting 6 to 8 weeks, the same dose should be continued for at least 6 months after full remission is achieved. 14 
Hormonal Treatment
Women experience dramatic hormonal shifts with the birth of a child. During pregnancy, levels of endogenous glucocorticoids and estrogens increase, only to plummet after delivery, producing a transient hypoactivation of the hypothalamicpituitary axis that lasts for weeks to months. Cizza et al 72 demonstrated that the suppression of the hypothalamic-pituitary axis is more severe and lasts longer in women who develop postpartum blues or depression. In a study of 23 women with severe postpartum depression, 16 had serum estradiol levels below the threshold for gonadal failure. 73 It follows, then, that the postpartum administration of exogenous hormones might be useful in blunting hormonal and mood declines in women who suffer from postpartum mood disorders.
In 2 prospective observational studies, a benefit to sublingual estrogen treatment of postpartum depression was found after only 2 weeks of treatment. 73, 74 These positive outcomes were substantiated in a randomized placebo-controlled trial of 61 depressed mothers. After 1 month, women in the treatment group (200 g of transdermal 17␤-estradiol administered daily) had fewer depressive symptoms than those in the control group, and this benefit persisted over the 6-month treatment period. 75 Estrogen may also be effective therapy for postpartum psychosis, according to a few case reports. 76, 77 In contrast, progesterone has not been shown to be beneficial in treating postpartum mood disorders, 78 and in fact may even be detrimental. 79 Additional trials should be conducted to confirm these findings and to evaluate the comparative benefit of hormonal versus antidepressant therapy for postpartum depression. Further research is also needed to assess the safety of estrogen treatment in the postpartum period, particularly as it relates to certain risks that are unique to or already increased in the postpartum period, such as decreased milk production in lactating women or thromboemboli.
Individual and Group Psychotherapy
Another approach to the treatment of postpartum depression is psychotherapy, administered as either an alternative or an adjunct to antidepressant drug therapy. Individual psychotherapy was found to be effective in 4 randomized controlled trials (Table  3) . Therapy was administered either by experienced psychotherapists, 82 trained health visitors, 21, 81 or both. 80 The number of psychotherapy sessions ranged from 6 to 12. The study by Appleby et al 21 was unique in that it compared individual psychotherapy with antidepressant therapy (fluoxetine)-both of which, as noted above, were found to be effective. A separate trial showed the value of including the partner in psychotherapy sessions. Women whose partners had participated in several psychotherapy sessions had lower Edinburgh Postnatal Depression Scores at the final assessment (which occurred 10 weeks after the first session) than those whose partners had not participated (8.6 vs 14.7, respectively). 86 Group therapy for mothers with postpartum depression has demonstrated mixed results: 2 studies found a benefit, 83,85 and 1 did not. 84 These inconsistent outcomes may have resulted from differences in the structure and/or content of the group therapy sessions. For example, in the 2 studies with positive outcomes, 83, 85 therapy sessions seemed to be more structured than in the study with negative outcomes (the former 2 studies offered education about such topics as postpartum depression, stress management, communication skills, and life planning, whereas the latter dealt with women's subjective views of childbirth, motherhood, and changing spousal relationships). More research is needed to determine whether group therapy may be helpful for certain populations of depressed mothers and, if so, the manner in which group therapy should be administered. 
Nurse Home Visits
Another type of postpartum support that has been studied, particularly in Europe, is that provided through nurse or midwife home visits. Two randomized controlled trials have shown a benefit from this type of intervention. In the first, 41 depressed mothers were randomized to a control group or a treatment group; treatment group participants received 6 weekly counseling visits by a Child Health Clinic nurse, who acted as a supportive listener. 87 Compared with the control group, the treatment group experienced a higher rate of recovery from postpartum depression (80% vs 25%). The second trial evaluated the benefit of a nurse home visit program for 181 women with adverse family characteristics. 88 Visits were made every week for 6 weeks, then every other week for an additional 6 weeks. During their visits, nurses provided guidance on childcare issues, facilitated access to community services, and reinforced successes. Here too, the treatment group showed better outcomes, with Edinburgh Postnatal Depression Scores of 5.7, compared with 7.9 in the control group.
Other Treatments
In addition to the previously described treatments for postpartum depression, certain physical modalities, such as light therapy, massage therapy, and electroconvulsive therapy, have been tested on a limited basis. Light therapy, often used for seasonal affective disorder, was evaluated in 2 depressed women-one who had been depressed for more than 4 months and refused antidepressant medication and another who been depressed for an unspecified length of time but had not responded to a trial of psychotherapy. 89 In both women, Hamilton Rating Scale for Depression scores fell markedly after 4 weeks of daily 30-minute phototherapy sessions (from 28 to 29 at baseline to 11 to 12 at follow-up). Field et al 90 evaluated massage therapy by randomizing 32 depressed adolescent mothers to relaxation or massage therapy, administered for 30 minutes on 2 consecutive days, for 5 weeks. Results showed that mothers in the massage group had less anxiety, less anxious behavior, and lower stress hormone levels after their sessions than did mothers in the relaxation therapy group. Electroconvulsive therapy, long used for non-postpartum depression, is also thought to be both effective and safe in the postpartum period. 91 Larger controlled studies on these and other nonpharmaceutical treatments for postpartum depression are needed to expand treatment options, particularly for breastfeeding women.
Summary
In conclusion, several treatments for postpartum depression have been found to be effective. These include individual psychotherapy and antidepressant drug therapy. Paroxetine, sertraline, and nortriptyline were among the most widely studied antidepressants for which no adverse effects on breastfeeding infants were reported. Other treatments that show promise in managing postpartum depression include estrogen therapy, nurse home visits, and possibly group therapy. More research is needed to identify additional effective treatments, particularly those that are safe for breastfeeding women. These treatments should be combined with patient education about the illness, the specific treatment selected, and other mechanisms for promoting health, such as social support and a healthy lifestyle.
